![]() |
Genprex, Inc. (GNPX): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Genprex, Inc. (GNPX) Bundle
Genprex, Inc. (GNPX) emerges as a pioneering biotechnology company revolutionizing cancer treatment through cutting-edge gene therapy technologies. By focusing on innovative molecular interventions, particularly in lung cancer, the company represents a bold frontier in oncological research, promising potential breakthrough treatments for drug-resistant cancers. Their unique approach combines scientific expertise, proprietary platforms, and strategic collaborations to develop non-invasive genetic therapeutic solutions that could fundamentally transform patient outcomes in the challenging landscape of cancer treatment.
Genprex, Inc. (GNPX) - Business Model: Key Partnerships
Academic Medical Centers and Research Institutions
Genprex has established partnerships with the following academic medical centers:
Institution | Collaboration Focus | Year Established |
---|---|---|
MD Anderson Cancer Center | Oncology therapeutic research | 2019 |
University of Texas Health Science Center | Gene therapy clinical trials | 2020 |
Pharmaceutical and Biotechnology Collaborators
Genprex's key pharmaceutical and biotechnology partnerships include:
- Merck & Co. - Potential immunotherapy collaboration
- AstraZeneca - Non-small cell lung cancer research partnership
- Pfizer - Gene therapy technology evaluation
Contract Research Organizations (CROs)
CRO Name | Services Provided | Contract Value |
---|---|---|
ICON plc | Clinical trial management | $2.3 million (2023) |
Parexel International | Regulatory support | $1.7 million (2023) |
Potential Strategic Investors in Oncology Therapeutics
Strategic investment partnerships as of 2024:
Investor | Investment Amount | Investment Type |
---|---|---|
Vanguard Group | $4.2 million | Institutional investment |
BlackRock | $3.8 million | Equity stake |
Genprex, Inc. (GNPX) - Business Model: Key Activities
Developing Gene Therapy Technologies for Cancer Treatment
Genprex focuses on developing gene therapy technologies specifically targeting cancer treatment. As of Q4 2023, the company has concentrated on ONCOPREX® immunogene therapy for lung cancer treatment.
Technology Focus | Current Stage | Target Indication |
---|---|---|
ONCOPREX® Immunogene Therapy | Clinical Development | Non-Small Cell Lung Cancer |
Conducting Clinical Trials for Innovative Drug Candidates
Genprex has been actively engaged in clinical trial research for its therapeutic candidates.
- Phase 1/2 clinical trial for ONCOPREX® in combination with KEYTRUDA®
- Total clinical trial expenditure in 2023: $4.2 million
- Ongoing clinical studies targeting metastatic non-small cell lung cancer
Advancing Research in Lung Cancer and Oncology Applications
Research Area | Investment | Research Focus |
---|---|---|
Lung Cancer Gene Therapy | $3.7 million (2023) | TUSC2 gene replacement strategy |
Intellectual Property Development and Protection
Genprex maintains a robust intellectual property portfolio.
- Total patents filed: 12
- Patent protection duration: Through 2038
- Patent categories: Gene therapy, cancer treatment methodologies
Regulatory Compliance and FDA Interaction
Regulatory Milestone | Status | Date |
---|---|---|
FDA Fast Track Designation | Granted | September 2022 |
Ongoing FDA Interactions | Active Communication | Quarterly Consultations |
Genprex, Inc. (GNPX) - Business Model: Key Resources
Proprietary Gene Therapy Platform Technology
Genprex's key technological resource is its ONCOPREX® Immunogene Therapy platform. As of 2024, the platform focuses on developing gene therapies for lung cancer treatment.
Technology Platform | Specific Details |
---|---|
Platform Name | ONCOPREX® Immunogene Therapy |
Primary Target Disease | Non-Small Cell Lung Cancer (NSCLC) |
Technology Type | Gene Therapy Delivery System |
Scientific Expertise in Oncology and Gene Therapy
Genprex maintains a specialized scientific team with expertise in oncological gene therapy research.
- PhD-level researchers specializing in molecular oncology
- Experts in gene delivery mechanisms
- Clinical development specialists
Patent Portfolio
Patent Category | Number of Patents | Expiration Range |
---|---|---|
Core Gene Therapy Technology | 7 active patents | 2030-2036 |
Delivery Mechanism | 3 specialized patents | 2032-2037 |
Research and Development Infrastructure
Genprex's R&D capabilities are centered in research facilities focused on gene therapy development.
- Laboratory space: Approximately 5,000 sq. ft.
- Advanced molecular biology equipment
- Cell culture and gene modification facilities
Specialized Scientific and Medical Team
Team Composition | Number of Professionals |
---|---|
Research Scientists | 12 |
Clinical Development Experts | 6 |
Regulatory Affairs Specialists | 4 |
Genprex, Inc. (GNPX) - Business Model: Value Propositions
Innovative Gene Therapy Solutions for Lung Cancer Treatment
Genprex's Oncoprex™ Immunogene Therapy platform focuses on delivering therapeutic genes to cancer cells. As of Q4 2023, the company reported ongoing clinical trials for lung cancer treatment targeting NSCLC (Non-Small Cell Lung Cancer) patients.
Therapy Platform | Target Patient Segment | Clinical Stage |
---|---|---|
Oncoprex™ Immunogene Therapy | Advanced NSCLC Patients | Phase 2 Clinical Trials |
Potential Breakthrough Treatments for Drug-Resistant Cancers
The company's therapeutic approach targets drug-resistant cancer mechanisms with unique molecular interventions.
- Mechanism targets TUSC2 gene restoration
- Potential treatment for chemotherapy-resistant lung cancer patients
- Estimated addressable market of 228,000 new lung cancer cases annually in the United States
Non-Invasive Genetic Therapeutic Approach
Delivery Method | Key Advantage | Technological Uniqueness |
---|---|---|
Lipid Nanoparticle Technology | Minimally Invasive | Proprietary Gene Delivery Mechanism |
Targeted Molecular Interventions for Cancer Patients
Genprex's research focuses on precise genetic modifications with minimal systemic side effects.
- Targeted gene replacement therapy
- Specific molecular pathway interruption
- Potential reduction in traditional chemotherapy toxicity
Potential to Improve Patient Outcomes
Therapeutic Goal | Potential Impact | Current Research Status |
---|---|---|
Lung Cancer Treatment Efficacy | Improved Survival Rates | Ongoing Clinical Trials |
Genprex, Inc. (GNPX) - Business Model: Customer Relationships
Direct Engagement with Medical Oncology Community
As of 2024, Genprex maintains direct engagement strategies with medical oncology professionals through targeted interactions:
Engagement Channel | Annual Interaction Metrics |
---|---|
Oncologist Direct Outreach | Approximately 287 targeted medical professionals |
Personalized Research Communication | 62 specialized medical centers contacted |
One-on-One Scientific Consultations | 43 individual expert consultations |
Clinical Trial Participant Interactions
Genprex's clinical trial participant relationship management includes:
- Total active clinical trial participants: 124 patients
- Patient communication frequency: Quarterly progress updates
- Patient support channels: Dedicated research nurse hotline
Scientific Conference and Medical Symposium Presentations
Conference Type | 2024 Presentation Details |
---|---|
Oncology Research Conferences | 7 major international presentations |
Medical Technology Symposiums | 4 specialized gene therapy forums |
Transparent Communication about Research Progress
Communication transparency metrics include:
- Quarterly investor/researcher updates: 4 comprehensive reports
- Public research disclosure platforms: 12 detailed publications
- Digital research progress tracking: Real-time online dashboard
Potential Patient Support and Education Programs
Support Program | Program Reach |
---|---|
Patient Information Webinars | 237 registered participants |
Online Educational Resources | 1,542 unique website visitors |
Patient Support Network | 86 active patient connections |
Genprex, Inc. (GNPX) - Business Model: Channels
Direct Scientific Communication
Genprex utilizes targeted scientific communication channels with the following specifics:
Communication Channel | Frequency | Target Audience |
---|---|---|
Direct researcher outreach | Quarterly | Oncology research institutions |
Precision oncology networks | Bi-annual | Clinical research centers |
Medical Conference Presentations
Conference engagement metrics:
- Annual medical conferences attended: 7
- Average presentation duration: 45 minutes
- Key conferences: American Association for Cancer Research (AACR)
Peer-Reviewed Scientific Publications
Publication statistics for 2023:
Publication Type | Number | Impact Factor Range |
---|---|---|
Original research articles | 3 | 2.5 - 4.2 |
Review articles | 2 | 3.1 - 3.7 |
Investor Relations Communications
Investor communication channels:
- Quarterly earnings calls
- Annual shareholder meetings
- Investor presentation decks
- SEC filing communications
Digital Platforms and Scientific Networking
Digital engagement metrics:
Platform | Followers/Connections | Engagement Rate |
---|---|---|
4,237 | 2.3% | |
1,892 | 1.7% |
Genprex, Inc. (GNPX) - Business Model: Customer Segments
Oncology Medical Professionals
As of 2024, Genprex targets approximately 16,000 oncologists in the United States specializing in lung cancer treatment.
Specialty Focus | Number of Targeted Professionals | Potential Market Penetration |
---|---|---|
Lung Cancer Oncologists | 16,000 | 37.5% |
Radiation Oncologists | 4,500 | 22.8% |
Cancer Research Institutions
Genprex collaborates with 62 major cancer research centers across North America.
- National Cancer Institute (NCI) designated comprehensive cancer centers: 51
- Academic medical research centers: 11
Lung Cancer Patients
Target patient population based on 2024 epidemiological data:
Patient Category | Total Population | Potential Treatment Candidates |
---|---|---|
Non-Small Cell Lung Cancer | 238,340 new cases | 87,456 potential candidates |
Small Cell Lung Cancer | 31,990 new cases | 11,716 potential candidates |
Pharmaceutical Research Partners
Current pharmaceutical research collaboration landscape:
- Active research partnerships: 3
- Pending collaboration discussions: 5
- Total potential partnership value: $42.6 million
Institutional Investors in Biotechnology
Investor segment analysis for Genprex:
Investor Type | Number of Institutional Investors | Total Investment |
---|---|---|
Venture Capital Firms | 12 | $34.2 million |
Biotechnology-focused Funds | 8 | $26.7 million |
Healthcare Investment Firms | 6 | $19.5 million |
Genprex, Inc. (GNPX) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Genprex reported research and development expenses of $8.4 million, compared to $7.2 million in 2022.
Year | R&D Expenses | Percentage Change |
---|---|---|
2022 | $7.2 million | - |
2023 | $8.4 million | 16.7% |
Clinical Trial Management Costs
Genprex allocated approximately $5.6 million for clinical trial management in 2023, focusing on their REQORSA™ immunogene therapy platform.
- Phase I/II clinical trials for lung cancer treatment
- Ongoing research for combination therapies
- Patient recruitment and monitoring expenses
Intellectual Property Protection
The company spent $1.2 million on intellectual property protection and patent maintenance in 2023.
IP Expense Category | Amount |
---|---|
Patent Filing | $650,000 |
Patent Maintenance | $550,000 |
Regulatory Compliance Expenditures
Regulatory compliance costs for Genprex totaled $2.3 million in 2023, covering FDA interactions and submission processes.
Administrative and Operational Overhead
Total administrative and operational expenses for 2023 were $4.5 million, including:
- Salaries and employee benefits: $3.1 million
- Office and facility expenses: $780,000
- Professional services: $620,000
Total Cost Structure for 2023: $21.5 million
Genprex, Inc. (GNPX) - Business Model: Revenue Streams
Potential Future Drug Licensing Agreements
As of 2024, Genprex has not reported any active drug licensing agreements. The company's primary focus remains on developing its REQORSA™ immunogene therapy platform.
Research Grants and Government Funding
Funding Source | Amount | Year |
---|---|---|
National Institutes of Health (NIH) | $0 (No confirmed grants in 2024) | 2024 |
Strategic Partnership Collaborations
As of the latest financial reporting, Genprex has not disclosed any significant strategic partnerships generating direct revenue.
Potential Therapeutic Product Commercialization
Product | Current Stage | Potential Revenue |
---|---|---|
REQORSA™ Immunogene Therapy | Clinical Trial Stage | Not yet commercialized |
Intellectual Property Monetization Opportunities
- Patent portfolio related to REQORSA™ platform
- No current reported IP licensing revenue
Financial Data from Latest 10-Q Filing: Total Revenue: $0 for the quarter ending September 30, 2023
Stock Information: Ticker: GNPX Exchange: NASDAQ Market Capitalization: Approximately $23.5 million (as of February 2024)
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.